Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia

NACompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

February 16, 2017

Primary Completion Date

November 30, 2017

Study Completion Date

December 8, 2017

Conditions
Chronic Widespread PainFibromyalgia
Interventions
DRUG

IGN-ES001

Only active product will be compared with placebo as described in Arms and Interventions.

DRUG

Parol 500 mg Tablets (acetaminophen)

Analgesic Rescue Medication

Trial Locations (23)

Unknown

Çukurova University School of Medicine, Adana

Akdeniz University School of Medicine, Antalya

Adnan Menderes University School of Medicine, Aydin

Uludağ University School of Medicine, Bursa

Onsekiz Mart University School of Medicine, Çanakkale

Trakya University School of Medicine, Edirne

Gaziantep University School of Medicine, Gaziantep

Bezmialem Vakıf University School of Medicine, Istanbul

İstanbul Physical Treatment and Rehabilitation Training and Research Hospital, Istanbul

İstanbul University Cerrahpaşa School of Medicine, Istanbul

İstanbul University İstanbul School of Medicine, Istanbul

Maltepe University School of Medicine, Istanbul

Marmara University Pendik Training and Research Hospital, Istanbul

Şişli Florence Nighingale Hospital, Istanbul

Şişli Hamidiye Etfal Training and Research Hospital, Istanbul

İzmir Medical Park Hospital, Izmir

Erciyes UNiversity School of Medicine, Kayseri

Necmettin Erbakan University School of Medicine, Konya

Sakarya University School Of Medicine Korucuk Training and Research Hospital, Sakarya

Cumhuriyet University School of Medicine, Sivas

Namık Kemal University School of Medicine, Tekirdağ

Karadeniz Technical University School of Medicine, Trabzon

Bülent Ecevit University School of Medicine, Zonguldak

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Scope International AG

INDUSTRY

collaborator

Klinar CRO

OTHER

collaborator

CenTrial GmbH

INDUSTRY

collaborator

Pharmasolutions4U

UNKNOWN

collaborator

idv Data Analysis and Study Planning

UNKNOWN

lead

IgNova GmbH

INDUSTRY

NCT03058224 - Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia | Biotech Hunter | Biotech Hunter